These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 1914782)
61. Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5-6 years. Tréluyer L; Zana-Taieb E; Jarreau PH; Benhammou V; Kuhn P; Letouzey M; Marchand-Martin L; Onland W; Pierrat V; Saade L; Ancel PY; Torchin H Arch Dis Child Fetal Neonatal Ed; 2024 Jun; 109(4):443-449. PubMed ID: 38228381 [TBL] [Abstract][Full Text] [Related]
62. The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. Engbers AGJ; Völler S; Poets CF; Knibbe CAJ; Reiss IKM; Koch BCP; Flint RB; Simons SHP Neonatology; 2021; 118(1):106-113. PubMed ID: 33626528 [TBL] [Abstract][Full Text] [Related]
63. Obstructive, mixed, and central apnea in the neonate: physiologic correlates. Finer NN; Barrington KJ; Hayes BJ; Hugh A J Pediatr; 1992 Dec; 121(6):943-50. PubMed ID: 1447664 [TBL] [Abstract][Full Text] [Related]
64. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Lee TC; Charles BG; Steer PA; Flenady VJ; Grant TC Br J Clin Pharmacol; 1996 Mar; 41(3):191-200. PubMed ID: 8866918 [TBL] [Abstract][Full Text] [Related]
65. Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. de Waal CG; Hutten GJ; Kraaijenga JV; de Jongh FH; van Kaam AH Neonatology; 2019; 115(1):85-88. PubMed ID: 30352445 [TBL] [Abstract][Full Text] [Related]
67. Maturational changes of theophylline pharmacokinetics in preterm infants. Dothey CI; Tserng KY; Kaw S; King KC Clin Pharmacol Ther; 1989 May; 45(5):461-8. PubMed ID: 2721102 [TBL] [Abstract][Full Text] [Related]
68. Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults. Haley TJ Drug Metab Rev; 1983; 14(2):295-335. PubMed ID: 6341027 [No Abstract] [Full Text] [Related]
69. Phenobarbital increases the theophylline requirement of premature infants being treated for apnea. Yazdani M; Kissling GE; Tran TH; Gottschalk SK; Schuth CR Am J Dis Child; 1987 Jan; 141(1):97-9. PubMed ID: 3788891 [TBL] [Abstract][Full Text] [Related]
70. Doxapram for apnea of prematurity. Rose SJ; Lloyd DJ; Duffty P J Pediatr; 1987 Jul; 111(1):154. PubMed ID: 3598780 [No Abstract] [Full Text] [Related]
71. Theophylline distribution in the premature neonate. Bonati M; Latini R; Marra G; Assael BM; Parini R Dev Pharmacol Ther; 1981; 3(2):65-73. PubMed ID: 7318639 [TBL] [Abstract][Full Text] [Related]
72. Second-degree atrioventricular heart block after doxapram administration. De Villiers GS; Walele A; Van der Merwe PL; Kalis NN J Pediatr; 1998 Jul; 133(1):149-50. PubMed ID: 9672531 [TBL] [Abstract][Full Text] [Related]
73. Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study. Huon C; Rey E; Mussat P; Parat S; Moriette G Acta Paediatr; 1998 Nov; 87(11):1180-4. PubMed ID: 9846921 [TBL] [Abstract][Full Text] [Related]
74. Low-dose doxapram for apnoea of prematurity. Bairam A; Vert P Lancet; 1986 Apr; 1(8484):793-4. PubMed ID: 2870280 [No Abstract] [Full Text] [Related]
75. Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. Banagale RC Med Hypotheses; 1982 Dec; 9(6):639-42. PubMed ID: 7167074 [TBL] [Abstract][Full Text] [Related]
76. [Recent acquisitions on the pharmacology and therapeutic uses of theophylline with special reference to cardiovascular effects]. Costa R; Marino A Clin Ter; 1991 Feb; 136(4):233-44. PubMed ID: 1827385 [TBL] [Abstract][Full Text] [Related]